ADM, a global leader in innovative solutions from nature, today announced that spore-forming probiotic DE111 (Bacillus subtilis) has received official approval from the Therapeutic Goods Administration (TGA), a part of the Australian Department of Health. This extends DE111’s availability into new regions, following the recent approval from the National Health Commission (NHC) in China.

“This is an important milestone for ADM, as it marks the first Bacillus subtilis strain to be approved by the TGA in Australia,” said Helen Hu, president of health & wellness APAC at ADM. “By expanding access to DE111, we’re facilitating new innovation possibilities for our Australian customers, enabling the development of pioneering gut health-supporting products. Additionally, the continued approval of DE111 by important government authorities demonstrates its high quality, safety and alignment with strict regulatory standards.”

Clinically documented results show that DE111:

• Supports digestive health1 and helps support healthy immune function.

• Can survive through the stomach and germinate in the small intestine.

• Can support a healthy gastrointestinal (GI) tract, gut function and microbiome diversity.

“DE111 is a spore-forming probiotic, which means it can withstand harsh formulation environments that may otherwise damage conventional probiotics. This robustness is paving the way for new, convenient and enjoyable foods, beverages and dietary supplements that meet people where they are on their wellness journeys, especially as more consumers make the connection between their gut and digestive health and other aspects of well-being,” continued Hu.

In Australia, 81% of consumers recognize a link between digestive health and overall well-being, and 76% specifically see a connection between their digestive health and immune function5. Plus, 64% of Australian consumers state that they have used probiotics/cultures to address digestive health concerns over the past 12 months. Simultaneously, the Australian probiotic supplement market is anticipated to grow, with Euromonitor reporting a forecasted CAGR of 2.7% between 2023 and 2028.